B cell activation pathways

B cell activation pathways represent the integrated network of signaling events that govern the transition of quiescent B cells into active, proliferating, and antibody-secreting cells (StatPearls, 2023). This process is primarily initiated by the B-cell receptor (BCR) recognizing specific antigens, which triggers a cascade of phosphorylation events involving kinases such as Lyn, Syk, and Bruton's tyrosine kinase (BTK) (UniProt, 2024). These signals ultimately lead to the activation of transcription factors that regulate cell survival, proliferation, and differentiation (PubMed, PMID: 31019211). In clinical contexts, these pathways are frequently dysregulated; for instance, constitutive BCR signaling is a driver in many B-cell malignancies, while over-activation contributes to the production of autoantibodies in systemic lupus erythematosus and rheumatoid arthritis (Nature Reviews Immunology, 2020). While B cell activation pathways is a broad term rather than a single target, many of its individual components are highly successful therapeutic targets for treating cancers and autoimmune disorders (NIH, 2023).

Other names

B-cell receptor signaling pathwayBCR signalingB-lymphocyte activationHumoral immune response activation

Modulation of B-cell activation through the inhibition of specific receptors (e.g., CD20, BAFF-R) or intracellular signaling enzymes (e.g., BTK, PI3K delta) to suppress pathological B-cell activity.